News Room


For Immediate Release – Xspire Pharma Files Utility Patent for Pharmaceutical Formulation

November 15, 2013
Xspire Pharma, a privately held pharmaceutical company, has filed a utility patent as a follow up to its provisional patent application, for the active ingredients (isometheptene mucate, caffeine, and acetaminophen) in combination with each other. The filing is based on the formulation of active ingredients together in a solid dosage form, based on certain percentages, and intended for oral consumption. Xspire Pharma currently holds a patent pending status for this formulation but is excited about its chances to receive an issued patent number from the USPTO. “We have worked diligently with the best patent team to make this a reality and look forward to the completed review and issue of our patent,” said Ford Mundy.

Legal Disclaimer:
It may take two or more years for the USPTO to review your application and determine whether to issue the patent. An issued patent starts protecting your invention as of its filing date with the USPTO. If you have filed a Provisional Application for Patent relating to the same invention, and your Non-Provisional Utility Patent Application is filed within 12 months of your Provisional Application, your filing date will be the filing date of your Provisional Application. If granted, legal action will be taken from patent issue date, back to the date of provisional patent application.

For Immediate Release – Xspire Pharma Launches SAVER EXPRESS for Nalfon.

November 20th, 2014
Xspire Pharma, a privately help pharmaceutical company, has launched SAVER EXPRESS™ for Nationwide Mail-Order Distribution of Nalfon (fenoprofen calcium) 400 mg Capsules. The program will allow Nalfon to be prescribed from any licensed Healthcare Provider in the United States and shipped via Next Day Shipping. The SAVER EXPRESS™ program will also provide Nalfon to patients with the maximum allowed saving to ensure the best price. To learn more about this program, please email customerservice@xspirerx.com.

For Immediate Release – FDA Approval of Butalbital, Acetaminophen, Caffeine Capsules

August 8th, 2017
Xspire Pharma, a privately help pharmaceutical company, today received FDA Approval for ANDA Butalbital, Caffeine, Acetaminophen Capsules.  The generic will be available immediately Nationwide and is AB rated to Fioricet Capsules.  To learn more about this program, please email customerservice@xspirerx.com.



//